Latest biosimilar drugs news
FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes
posted February 19th
by modernClinician Editorial Team
by modernClinician Editorial Team
FDA Approves Wezlana for Multiple Inflammatory Diseases
posted November 2nd
by modernClinician Editorial Team
by modernClinician Editorial Team
More Biosimilars Marketed in Germany, Switzerland Than U.S.
posted December 2nd
by modernClinician Editorial Team
by modernClinician Editorial Team
More Biosimilars Marketed in Germany, Switzerland Than U.S.
posted December 2nd
by modernClinician Editorial Team
by modernClinician Editorial Team
Editor's Recommendations
Long-Term Medication Adherence Tied to Lower Cardiovascular Event Rate in Type 2 Diabetes 
Cancer-Attributable Costs High for Seniors, Vary With Cancer Phase, Type, Race .jpg)
Once-Weekly Oral Islatravir-Lenacapavir Noninferior to Daily B/F/TAF in HIV 
28 Percent of U.S. Adults With HTN Eligible for Treatment Under New Guidelines 
Biosimilars Could Cut Spending for Biologic Therapy in the U.S. 
FDA OKs 1st Biosimilar to Prevent Chemo-Related Infections Monthly Specialist Briefings
Stay Connected
